PEPTIDES FOR MUSCLE GROWTH

Direct anabolic peptides like IGF-1 LR3 act on the IGF-1 receptor and drive skeletal-muscle hypertrophy in rodent models. Growth-hormone secretagogues like CJC-1295 plus Ipamorelin raise endogenous GH and IGF-1 pulses. BPC-157 and TB-500 act on tissue repair rather than direct hypertrophy, but accelerate recovery between training stress events. No clean head-to-head human RCT compares these compounds for hypertrophy.

The Wolverine stack pairs BPC-157 (angiogenesis, VEGF, NO, growth-hormone-receptor upregulation) with TB-500 (G-actin sequestration, cell migration). The two mechanisms are complementary rather than competitive. Animal-model evidence is the basis for combining them in community protocols. No published RCT validates the specific combination in humans. See /vs/bpc-157-vs-tb-500 for the full comparison.

Growth-hormone secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, Tesamorelin) are prohibited at all times by WADA for athletes in tested sport. They are not FDA-approved as prescription drugs in the United States except for tesamorelin in HIV-associated lipodystrophy. Research-grade reference compounds are sold for in-vitro laboratory use only.

Anabolic-androgenic steroids are testosterone derivatives that bind androgen receptors and drive direct protein synthesis. Research peptides act through different receptors: growth-hormone secretagogues raise endogenous GH, IGF-1 LR3 binds the IGF-1 receptor, BPC-157 and TB-500 act on tissue-repair pathways. Mechanisms, side-effect profiles, and regulatory status are all different. Both classes are off-label for muscle growth in the United States.